Press Release
Stay updated with our latest news and media
Daewoong and Indonesia Growing Together for 20 Years... Awarded ‘2025 Best Innovation in Biotechnology Award’
Writer
Manager
September 16, 2025
- Pioneering “Firsts” in Indonesia: First Biosimilar, Halal Pharmaceuticals, and Stem Cell Production Facilities
- Established Four Research Institutes in Collaboration with UI, ITB, and IPB, Leading Local R&D Ecosystem Development
- Currently Invested 2.9 Trillion Rupiah, Plans to Expand Total Investment to 5.26 Trillion Rupiah by 2028

Daewoong has been recognized for 20 years of collaborative growth in Indonesia’s healthcare sector and has become the first Korean company to receive the prestigious ‘2025 Prominent Award’ for Biotechnology Best Innovation.

The ‘Prominent Award 2025’ is one of Indonesia’s most authoritative awards, given annually to organizations and companies across various industries that have contributed to national development through innovation and achievement. This year’s theme, “Transforming Indonesia,” selected 15 companies that strengthened industrial competitiveness and improved the quality of life for Indonesian citizens.

 

Head of Daewoong’s Indonesian Business Division, stated, “Winning the Biotechnology Innovation Award this year marks a new starting point beyond the achievements of the past 20 years. Daewoong will continue to introduce innovative drugs and advanced technologies to Indonesia and promote joint growth with the Indonesian pharmaceutical and biotechnology industry through local production and collaborative research.”

◆Strengthening Local Production Capacity through Technology Transfers from cGMP-level Biopharmaceutical Plants to Stem Cells

Daewoong has laid the groundwork for Indonesia to become self-reliant in biopharmaceuticals and a leader in regenerative medicine. The company led efforts to build previously nonexistent plant facilities and transfer production technologies, thereby enhancing the sustainability of Indonesia’s healthcare industry.

In 2012, Daewoong established a joint venture, Daewoong Infion, and completed Indonesia’s first cGMP-level biopharmaceutical manufacturing plant. Through this, active pharmaceutical ingredients such as EPO and EGF have been produced locally, and in 2017, the company launched Indonesia’s first biosimilar, ‘Epodion’.

In particular, to ensure safe treatment environments for Indonesian patients, Daewoong pursued Halal certification rigorously. In 2020, ‘Epodion’ an animal cell-derived biopharmaceutical for anemia treatment, became the world’s first to obtain Halal certification. The same year, the diabetic foot ulcer treatment, ‘Easyef’ also received Halal certification.

Continuing its advancements, Daewoong constructed a plant in Cikarang capable of producing stem cell therapies and became the first Korean company to receive GMP certification for this facility. The plant can independently manufacture a full pipeline of cell-based therapies, including autologous stem cells, NK cells, exosomes, and culture media. This achievement presents hope for patients facing limits in conventional treatments by enabling personalized cell therapies and promotes improved access to precision medicine.

Research Institutes with UI, ITB, and IPB Cultivating Over 700 Pharmaceutical and Biotech Talents

Daewoong is also accelerating the enhancement of clinical capabilities within Indonesia’s healthcare sector, recognizing clinical expertise as a sustainable growth driver.

The Daewoong Foundation has partnered with Indonesia’s University of Indonesia (UI), Bandung Institute of Technology (ITB), and Bogor Agricultural University (IPB) to establish four research institutes. These institutes provide exceptional facilities and mentoring programs to foster talented researchers, going beyond material support to nurture future innovators. Research support includes cutting-edge fields such as stem cells, gene editing, organoids, and drug delivery systems. Since its inception as a scholarship program in 2009, the Daewoong Foundation has supported the development of over 700 talented individuals.

◆With a Total Investment of 5.26 Trillion Rupiah… Striving to Become Indonesia’s No. 1 Pharmaceutical and Biotech Company by 2030

Daewoong has invested approximately 2.9 trillion rupiah in Indonesia to date and plans to expand its total investment to 5.26 trillion rupiah, aiming to become Indonesia’s No. 1 pharmaceutical and biotechnology company by 2030.

Daewoong’s investments span broadly across healthcare sectors in Indonesia, including technology transfers for botulinum toxin production, innovative drug development, improved formulations and delivery technologies, biopharmaceuticals, stem cells, medical devices, aesthetics, open collaboration projects, scholarship programs, and wellness initiatives. Daewoong’s genuine commitment to being a healthcare partner for Indonesians is expected to contribute significantly not only to health improvement and industrial development but also to job creation.

recent post
Forward
Press Release
Daewoong and Indonesia Growing Together for 20 Years... Awarded ‘2025 Best Innovation in Biotechnology Award’
Press Release
Daewoong Advances GERD Treatment Innovation in Indonesia through Fexuprazan IIT Study